Sunovion Pharmaceuticals Inc. Release: Latuda(R) (lurasidone HCl) was Associated with Low Rates of Weight Gain and Metabolic Changes in Patients with Schizophrenia in Data Presented at the 164th Meeting of the American Psychiatric Association

MARLBOROUGH, Mass.--(BUSINESS WIRE)--Sunovion Pharmaceuticals Inc. today announced results from a new pooled data analysis on weight and metabolic parameters across short- and long-term studies in adult patients with schizophrenia treated with Latuda® (lurasidone HCl) tablets. These data were presented at the Annual Meeting of the American Psychiatric Association in Honolulu, Hawaii.